M2451635
Edicotinib , ≥99% , 1142363-52-7
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB1579.20 | In Stock |
|
| 10mg | RMB2631.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Density | 1.19±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO:23.34(Max Conc. mg/mL);50.56(Max Conc. mM) DMSO:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.54(Max Conc. mM) DMF:30.0(Max Conc. mg/mL);64.99(Max Conc. mM) Ethanol:20.0(Max Conc. mg/mL);43.33(Max Conc. mM) |
| form | A crystalline solid |
| pka | 13.82±0.70(Predicted) |
| color | White to off-white |
| InChIKey | BNVPFDRNGHMRJS-UHFFFAOYSA-N |
| SMILES | C1(C(NC2=CC=C(C3CC(C)(C)OC(C)(C)C3)N=C2C2CCC(C)(C)CC=2)=O)NC(C#N)=CN=1 |
Description and Uses
Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively[1]. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research[1][2].
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
